Our Partners
Expertise Partners

genOway
genOway is a biotechnology company offering preclinical models and solutions, especially genetically-modified mouse, rat and cell line models, to biopharmaceutical companies, CROs and academic institutions worldwide. Its goal is to provide ultimate predictability in preclinical research to help its clients select the best therapeutics to accelerate drug development from bench to bedside.
Exhibition Partners

Thermo Fisher
Thermo Fisher provides a broad portfolio of proven, consistently high-performing Gibco™ products and equipment to meet the demands of cell therapy innovators. Going beyond products and equipment, our trusted and experienced support can help guide you toward optimal therapeutic outcomes. Gibco™ Cell Therapy Systems (CTS™) solutions have been designed with efficiency in mind, supporting streamlined cell therapy development and manufacturing so you can get your life-changing treatments to patients fast.
Industry Partners

Harvard Medical School
The Immunobiology Laboratories at Harvard Medical School and Massachusetts General Hospital perform studies on the basic biology TNF superfamily receptors, with an emphasis on autoimmunity and cancer. TNFR2 identifies Treg cells with the highest potency; in human cancers TNFR2 is overexpressed in the tumor microenvironment and in autoimmunity it is under expressed on Tregs. Recent data suggests agonistic TNFR2 antibodies can be made (Science Signaling 2020). For potent TNF superfamily agonism or antagonism, the final surface structures must have either tight hexagonal networks (agonism) or larger
hexagonal networks (antagonism). Humanized antibodies to TNFR2 have now been produced using these principle with broad verification of these desired structural constructs.
Event Partners

eXmoor pharma
eXmoor pharma is a full service Cell & Gene Therapy CDMO with a difference. We are backed by 20 years consultancy experience supporting over 150 organisations accelerate novel therapies from discovery to patients. We provide expert solutions at all stages of the development journey from early process development and scale-up through to GMP manufacture, fill and finish and QP release.

Beacon
Beacon are a clinical trial and pipeline database solution designed in partnership with
pharmaceutical professionals. Beacon track targeted therapies to provide accurate, indepth,
and real-time information in the rapidly evolving drug development landscape.
For more information or to request a demo, visit our website: